(NASDAQ: CVKD) Cadrenal Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Cadrenal Therapeutics's earnings in 2025 is -$10,651,368.On average, 3 Wall Street analysts forecast CVKD's earnings for 2025 to be -$8,671,666, with the lowest CVKD earnings forecast at -$10,827,130, and the highest CVKD earnings forecast at -$5,225,594. On average, 3 Wall Street analysts forecast CVKD's earnings for 2026 to be -$5,169,203, with the lowest CVKD earnings forecast at -$5,733,116, and the highest CVKD earnings forecast at -$4,135,362.
In 2027, CVKD is forecast to generate -$2,951,145 in earnings, with the lowest earnings forecast at -$2,951,145 and the highest earnings forecast at -$2,951,145.